<DOC>
	<DOCNO>NCT02725515</DOCNO>
	<brief_summary>The purpose study determine ability XmAb5871 maintain Systemic Lupus Erythematosus ( SLE ) disease activity improvement achieve brief course disease-suppressing steroid therapy</brief_summary>
	<brief_title>A Study Effect XmAb®5871 Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Patients diagnosis SLE define ACR criterion Patients history ( + ) ANA , ( + ) ENA ( + ) antidsDNA serology document within one year prior randomization Investigator assess patient judgment , SLE disease activity organ threaten Both investigator patient agree acceptable discontinue current immunosuppressant SLE medication receive brief course IM steroid therapy If patient oral steroid , must equivalent ≤15 mg/day prednisone enter screening , must able taper ≤10 mg/day randomization History evidence clinically unstable/uncontrolled disorder , condition disease , SLE , opinion investigator would pose risk patient safety interfere study evaluation , procedure completion Patients organ threaten manifestation SLE include active Class 3 4 lupus nephritis require induction maintenance therapy disorder stop SLE therapy contraindicate Active CNS lupus seizure psychosis opinion investigator would preclude participation Unstable hemolytic anemia thrombocytopenia Patient pregnant breast feeding , plan become pregnant participate study Use biologic therapy ( include belimumab ) within 6 month randomization , prior exposure monoclonal antibody direct CD20 ( rituximab ) within 12 month randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>